Diagnostic Consultative Center 1 Lom EOOD
- Address
- lock Available on a paid plan
Cardiovascular Disease and Kidney Health
At Diagnostic Consultative Center 1 Lom EOOD, clinical research in cardiovascular diseases and nutritional and metabolic diseases focuses on conditions such as chronic kidney disease, hypertension, and heart failure. These studies are designed to assess whether new treatments can better slow disease progression, reduce major heart and kidney complications, and improve everyday outcomes for patients.
- Research in chronic kidney disease and hypertension aimed at slowing kidney decline and lowering related risks
- Studies in heart failure, including HFpEF and HFmrEF, evaluating ways to reduce hospital visits and improve symptoms
- Trials in obesity linked to heart disease, exploring whether treatment can support better weight and cardiovascular outcomes
This work reflects a strong interest in treatments that may improve long-term protection for the heart, kidneys, and metabolic health.
Immune-Mediated Disease Research
The site also supports studies in immune system diseases, especially rheumatoid arthritis. These trials are evaluating new and existing treatment approaches to help control inflammation, ease symptoms, and improve function in people living with active joint disease.
- Clinical research in rheumatoid arthritis focused on reducing inflammation and improving disease control
- Comparisons of treatment options for patients already using or starting methotrexate
- Studies intended to improve the effectiveness and tolerability of therapy in moderate to severe rheumatoid arthritis
This area highlights the center’s role in testing therapies that may offer better symptom relief and long-term disease management.
Respiratory and Viral Infection Studies
Research in respiratory tract diseases and virus diseases includes studies of respiratory syncytial virus and COVID-19. These trials are designed to see whether new antiviral treatments can reduce the chance of worsening illness and support recovery in people at higher risk of complications.
- Studies in RSV infection focused on easing symptoms and preventing progression to more serious disease
- Trials in COVID-19 for nonhospitalized patients at high risk of severe illness
- Research aimed at improving treatment options for common viral respiratory infections
The research activity in this area shows a clear focus on early intervention and better outcomes for vulnerable patients with respiratory infections.
Obesity and Metabolic Health
The clinical trial portfolio at this laboratory and research facility also includes work on obesity and related metabolic conditions. These studies are examining whether new therapies can help reduce body weight, support weight maintenance, and improve outcomes when obesity is linked with heart failure or other chronic illness.
- Trials in obesity evaluating weight reduction and maintenance strategies
- Research in patients with heart failure and excess body weight to explore broader health benefits
- Studies looking at treatment approaches that may improve both metabolic and cardiovascular risk
This area connects weight management with broader goals in heart and metabolic care, reflecting an integrated approach to chronic disease research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic Consultative Center 1 Lom EOOD
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baxdrostat | 2 | Unknown | 2024-06-05 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.